Navigation Links
Ardea Biosciences Announces Changes to Research Management
Date:10/5/2007

on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which has been cleared by the FDA to enter Phase 1 clinical trials, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of establishing a collaboration with a new non-profit foundation to leverage Ardea's early discovery assets for neglected diseases in developing countries, its goal of initiating Phase 1 clinical studies of RDEA119 and initiating clinical studies on three additional compounds this year, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... A study has been launched to test ... track could help to tackle the problem of obesity.  This ... GP surgery based in Stowmarket) and academics at University Campus ... Telemetry technology, which is inspired by equipment used to collect ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Small Tree Communications , a supplier of high-performance networking ... software protocol called Blaze, expected to ship in the third ... High-Definition digital video editing. , ,Blaze will make it ... on the newer high-end 10 gigabit Ethernet cards. It ...
... Corporation and Middleton-based Bone Care International Inc. announced ... their proposed merger. , ,Genzyme and Bone Care have signed ... Care in an all-cash transaction valued at $33.00 per ... by Bone Care's shareholders at a meeting on ...
... - Stratatech Corp. was awarded a federal ... of General Medical Sciences to further develop its engineered human ... Madison and employs 18 people, according to the 2005 edition ... Its products are based on a source of pathogen-free human ...
Cached Biology Technology:Small Tree is streamlining digital video editing 2Small Tree is streamlining digital video editing 3
(Date:4/22/2014)... the University of Kentucky has discovered new methods to ... , The research, led by Peixuan Guo, professor and ... UK College of Pharmacy and Markey Cancer Center, is ... Anionic Polymer Material To Build Robust Structures with Defined ... Daniel L. Jasinski. , The article, which will appear ...
(Date:4/22/2014)... a trip to Asia to coordinate with allies ... officials at the Office of Naval Research (ONR) ... (APTEP) as an example of strong and growing ... in the region. , The APTEP program, centered ... supports the development of alternative energy technologies. It ...
(Date:4/22/2014)... is another way of asking him or her to ... Certain cells of the immune system tend to misbehave ... Because these cells are known to misbehave similarly during ... immune cells to better understand how our immune systems ... Institute on Aging, part of the National Institutes of ...
Breaking Biology News(10 mins):RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3For an immune cell, microgravity mimics aging 2For an immune cell, microgravity mimics aging 3For an immune cell, microgravity mimics aging 4For an immune cell, microgravity mimics aging 5
... who must stay awake for long shifts ?soldiers, pilots, ... from new research showing that preventing the gas nitric ... off the sleep urge. , The research, conducted by ... Helsinki (Helsinki, Finland), ties together previous observations about sleep ...
... scientists have engineered yeast cells capable of producing ... fully human sugar structures (glycosylation). These sugar structures ... to date, have necessitated the expression of therapeutic ... has the potential to eliminate the need for ...
... Emory University's Winship Cancer Institute have identified a novel ... role the marker may play when the tumor spreads ... is elevated in the cerebrospinal fluid of patients with ... in the November issue of Clinical Cancer Research. ...
Cached Biology News:Need to pull an all-nighter? 2GlycoFi and Dartmouth report full humanization of yeast glycosylation pathway in Science 2Newly identified biomarker detects and regulates spread of brain tumors 2
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry....
PGD2-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGD2 by GC- or LC-mass spectrometry....
Request Info...
Biology Products: